CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transpla
Go back to CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transpla| CORMEDIX, Inc. (NASDAQ: CRMD) | Delayed: 8.82 +0.15 (1.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.67 | 52 Week High | $4.54 | |||
| Open | $8.70 | 52 Week Low | $1.15 | |||
| Day High | $9.06 | P/E | N/A | |||
| Day Low | $8.70 | EPS | $-0.55 | |||
| Volume | 1,957,729 | |||||
